16:35 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Fibrotic disease company Pliant raises $62M series B

Fibrosis play Pliant Therapeutics Inc. (Redwood City, Calif.) raised $62 million on July 16 in an untranched series B round led by Cowen Healthcare Investments. Fellow new investors Eventide Asset Management, Schroder Adveq, Menlo Ventures,...
17:45 , Jul 18, 2018 |  BioCentury  |  Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday,...
16:45 , Jul 16, 2018 |  BC Extra  |  Financial News

Fibrotic disease company Pliant raises $62M series B

Fibrosis play Pliant Therapeutics Inc. (Redwood City, Calif.) raised $62 million in an untranched series B round led by Cowen Healthcare Investments. Fellow new investors Eventide Asset Management, Schroder Adveq, Menlo Ventures, SCubed Capital, Agent...
07:00 , Oct 17, 2016 |  BioCentury  |  Emerging Company Profile

Integrins go oral

Morphic Therapeutic Inc. is combining an understanding of the structural biology of integrins with computational chemistry to solve the problems that have prevented development of oral integrin inhibitors. The company is initially developing candidates for...
08:00 , Mar 7, 2016 |  BioCentury  |  Emerging Company Profile

Fibrosis frontal attack

Pliant Therapeutics Inc. was formed to develop fibrosis products based on collaborative work by UCSF biologists and chemists that identified the primary culprit of TGF beta activation, along with small molecules that can inhibit that...
08:00 , Feb 22, 2016 |  BioCentury  |  Finance

Fixing fibrosis

The combination of new mechanistic insights into how to modulate IPF and regulatory clarity around the disease convinced Third Rock Ventures to form a company focused on therapeutics that can halt and reverse fibrosis. The...
01:51 , Feb 19, 2016 |  BC Extra  |  Financial News

Third Rock fibrosis play debuts with $45M

Third Rock Ventures launched fibrosis company Pliant Therapeutics Inc. (Redwood City, Calif.) with a $45 million series A round. The biotech is developing a small molecule inhibitor of integrin alpha(V)beta(1) ( CD51/CD29 ) to treat...
07:00 , Apr 10, 2014 |  BC Innovations  |  Cover Story

Pre-EMP-tive strike against GBM

University of California, Los Angeles researchers have treated glioblastoma in mice by inhibiting epithelial membrane protein 2 . 1 The findings open up a new indication for spinout Paganini Biopharma Inc. , which has a...
07:00 , Sep 12, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

This week in techniques Approach Summary Licensing status Publication and contact information Imaging Intracranial imaging of medulloblastomas with fluorescent-tagged, integrin-binding knottin peptide A peptide-based imaging agent could help guide surgical resection of medulloblastomas. In vitro,...